Literature DB >> 16314616

Hormone replacement therapy is associated with decreased survival in women with lung cancer.

Apar Kishor Ganti1, Abe E Sahmoun, Amit W Panwalkar, Ketki K Tendulkar, Anil Potti.   

Abstract

PURPOSE: Lung cancer is the leading cause of cancer-related death in women. Hormone replacement therapy (HRT) is frequently prescribed to postmenopausal women, but there is little data on its effect on lung cancer. Hence, we conducted a retrospective study to examine the impact of HRT on the natural history of lung cancer.
METHODS: We conducted a retrospective chart review of women diagnosed with lung cancer between January 1994 and December 1999. Data collected included age, stage, past history of cancer, smoking history, family history of cancer, HRT use, treatment, and overall survival. The effects of various clinical features on survival were examined using Cox proportional hazards regression models.
RESULTS: Four hundred ninety-eight women (median age, 67 years; range, 31 to 93 years) with lung cancer were included. A history of smoking was present in 429 women (86%), whereas 86 women (17%) had taken HRT. Women with lung cancer who received HRT were younger than women with lung cancer who never received HRT (63 v 68 years old, respectively; P < .0001). Overall survival was significantly higher in patients with no HRT compared with patients who received HRT (79 v 39 months, respectively; hazard ratio = 1.97; 95% CI, 1.14 to 3.39). This effect seemed to be more pronounced in women with a smoking history.
CONCLUSION: HRT may affect outcomes from lung cancer adversely. Further studies examining the role of HRT use on outcomes from lung cancer, especially in women with a history of smoking, are urgently needed to clarify this important problem.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16314616     DOI: 10.1200/JCO.2005.02.9827

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  65 in total

1.  Targeting the estrogen pathway for the treatment and prevention of lung cancer.

Authors:  Timothy F Burns; Laura P Stabile
Journal:  Lung Cancer Manag       Date:  2014-02-01

2.  Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women.

Authors:  Susan E Olivo-Marston; Leah E Mechanic; Steen Mollerup; Elise D Bowman; Alan T Remaley; Michele R Forman; Vidar Skaug; Yun-Ling Zheng; Aage Haugen; Curtis C Harris
Journal:  Carcinogenesis       Date:  2010-08-20       Impact factor: 4.944

Review 3.  Lung cancer in women.

Authors:  Angela M Coscio; Jennifer Garst
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

4.  Interplay between estrogen and Stat3/NF-κB-driven immunomodulation in lung cancer.

Authors:  Shanshan Deng; Marco Ramos-Castaneda; Walter V Velasco; Michael J Clowers; Berenice A Gutierrez; Oscar Noble; Yiping Dong; Melody Zarghooni; Lucero Alvarado; Mauricio S Caetano; Shuanying Yang; Edwin J Ostrin; Carmen Behrens; Ignacio I Wistuba; Laura P Stabile; Humam Kadara; Stephanie S Watowich; Seyed Javad Moghaddam
Journal:  Carcinogenesis       Date:  2020-11-13       Impact factor: 4.944

5.  The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer.

Authors:  Nadiyah Kazmi; Diana C Márquez-Garbán; Lilia Aivazyan; Nalo Hamilton; Edward B Garon; Lee Goodglick; Richard J Pietras
Journal:  Lung Cancer Manag       Date:  2012-12

Review 6.  Estrongenic steroid hormones in lung cancer.

Authors:  Jill M Siegfried; Laura P Stabile
Journal:  Semin Oncol       Date:  2013-12-12       Impact factor: 4.929

7.  Prediagnosis soy food consumption and lung cancer survival in women.

Authors:  Gong Yang; Xiao-Ou Shu; Hong-Lan Li; Wong-Ho Chow; Wanqing Wen; Yong-Bing Xiang; Xianglan Zhang; Hui Cai; Bu-Tian Ji; Yu-Tang Gao; Wei Zheng
Journal:  J Clin Oncol       Date:  2013-03-25       Impact factor: 44.544

8.  Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial.

Authors:  Rowan T Chlebowski; Heather Wakelee; Mary Pettinger; Thomas Rohan; Jingmin Liu; Michael Simon; Hilary Tindle; Catherine Messina; Karen Johnson; Ann Schwartz; Margery Gass; Jean Wactawski-Wende
Journal:  Clin Lung Cancer       Date:  2015-10-22       Impact factor: 4.785

9.  Hormone replacement therapy and outcomes for women with non-small-cell lung cancer: can an association be confirmed?

Authors:  O Ayeni; A Robinson
Journal:  Curr Oncol       Date:  2009-05       Impact factor: 3.677

10.  Antiproliferative effect of exemestane in lung cancer cells.

Authors:  Angelos Koutras; Efstathia Giannopoulou; Ismini Kritikou; Anna Antonacopoulou; T R Jeffry Evans; Athanasios G Papavassiliou; Haralabos Kalofonos
Journal:  Mol Cancer       Date:  2009-11-24       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.